Kalinowsky et al. observed that in HN5 (erlotinib-sensitive), SCC-25 (intermediate sensitivity), and FaDu (erlotinib-resistant) head and neck cancer cells, miR-7 binds to EGFR mRNA, decreasing the levels of p-EGFR and p-Akt. Here, EGFR is linked to head and neck cancer.